ICS-283: a system for targeted intravenous delivery of siRNA

Raymond M Schiffelers, Gert Storm
2006 Expert Opinion on Drug Delivery  
ICS-283 was developed within Intradigm Corporation as a system that is designed for the systemic delivery of therapeutic small interfering (siRNA) to sites of pathological angiogenesis. The non-viral siRNA delivery system is based on synthetic nanoparticles, known as TargeTran™ (Intradigm Corporation), which functions as a broad-platform technology to deliver siRNA to specific target cells in diseased tissues. The system is constructed to incorporate different functionalities that address
more » ... that address critical needs for successful nucleic acid delivery. The TargeTran synthetic vector is a self-assembling, layered nanoparticle that protects and targets siRNA to specific cell types in pathological tissues. At present, ICS-283 is the only antiangiogenic siRNA delivery system that is designed for intravenous administration to treat angiogenesis-driven diseases.
doi:10.1517/17425247.3.3.445 pmid:16640503 fatcat:65nluyfovjgilg36hsyo5qpc5i